Perspective Therapeutics
CATX
Market cap $193M

2.85 USD

+0.01

0.35%

At close Dec 20, 4:00 PM EST

After hours

2.95

+0.10

3.51%

1 day

0.35%

5 days

-17.87%

1 month

-53.81%

3 months

-78.46%

6 months

-73.24%

Year to date

-28.93%

1 year

-16.67%

5 years

-52.34%

10 years

-81.13%

About: Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides.

Employees: 119

Healthcare Surgical & Medical Instruments & Apparatus

0

Funds holding %

of 6,809 funds

0

Analysts bullish %

of 6 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

110% more first-time investments, than exits

New positions opened: 42 | Existing positions closed: 20

100% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 2 (+1) [Q3]

92% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 24

69% more capital invested

Capital invested by funds: $386M [Q2] → $655M (+$269M) [Q3]

21% more funds holding

Funds holding: 105 [Q2] → 127 (+22) [Q3]

15.28% more ownership

Funds ownership: 57.56% [Q2] → 72.84% (+15.28%) [Q3]

98% less call options, than puts

Call options by funds: $25K | Put options by funds: $1.37M

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$6

111%

upside

Avg. target

$16.50

479%

upside

High target

$21

637%

upside

6 analyst ratings

5 positive

83%

1 neutral

17%

0 negative

0%

RBC Capital Gregory Renza 40% 1-year accuracy 32 / 81 met price target	461%upside $16	Outperform Maintained	25 Nov 2024
B of A Securities Alec Stranahan 25% 1-year accuracy 1 / 4 met price target	111%upside $6	Neutral Downgraded	25 Nov 2024
Oppenheimer Jeff Jones 24% 1-year accuracy 10 / 41 met price target	461%upside $16	Outperform Maintained	22 Nov 2024
Wedbush David Nierengarten 38% 1-year accuracy 49 / 128 met price target	602%upside $20	Outperform Reiterated	24 Oct 2024
UBS David Dai 18% 1-year accuracy 2 / 11 met price target	602%upside $20	Buy Initiated	24 Oct 2024

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about CATX published over the past 30 days

Perspective Therapeutics: Definitely Not Looking Overvalued Now

Perspective Therapeutics' novel alpha emitter PRRT shows promise in early trials, with manageable toxicity and durable disease control in GEP-NETs and melanoma. Strong cash position allows CATX to continue research for years, despite current market skepticism and a significant drop in valuation. Alpha emitter PRRT offers a potentially safer alternative to beta emitters, but faces challenges in manufacturing, handling, and market uptake.

Perspective Therapeutics: Definitely Not Looking Overvalued Now

Perspective Therapeutics to Participate in Upcoming Investor Conferences in December

SEATTLE, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences.

Perspective Therapeutics to Participate in Upcoming Investor Conferences in December

Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium

SEATTLE, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, announced initial results from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET that are being presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium taking place November 21-23, 2024 in Chicago.

Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium

Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024

SEATTLE, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today released details regarding the upcoming presentation of initial results from the Company-sponsored Phase 1/2a trial of [212Pb]VMT-α-NET at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium taking place November 21-23, 2024 in Chicago.

Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results

SEATTLE, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc . (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced third quarter financial results for the period ended September 30, 2024.

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results

Perspective Therapeutics to Participate in Upcoming Investor Conferences in November

SEATTLE, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences.

Perspective Therapeutics to Participate in Upcoming Investor Conferences in November

Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine

SEATTLE, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced six updates on the Company's radiopharmaceutical programs being presented at the 37th Annual Congress of the European Association of Nuclear Medicine ("EANM") held in Hamburg, Germany, from October 19-23, 2024.

Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine

Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey

SEATTLE, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today is celebrating the first shipment and patient dosing from its second manufacturing facility for the production of its 203Pb- and 212Pb-labeled radiopharmaceuticals.

Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey

Cancer-Focused Perspective Therapeutics Stock Trades Lower After Drug Study Report

Perspective Therapeutics, Inc. CATX is down 13% at $11.53 at last check Friday.

Cancer-Focused Perspective Therapeutics Stock Trades Lower After Drug Study Report

Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research

SEATTLE, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that initial results from its Phase 1/2a study of [212Pb]VMT01 are being presented at the 21st International Congress of the Society for Melanoma Research (“SMR”), being held on October 10-13, 2024 in New Orleans, Louisiana.

Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research

See News Rankings

Charts implemented using Lightweight Charts™